Westwood Holdings Group Inc. Increases Holdings in Prestige Consumer Healthcare Inc. $PBH

Westwood Holdings Group Inc. raised its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 881,908 shares of the company’s stock after acquiring an additional 20,626 shares during the quarter. Westwood Holdings Group Inc.’s holdings in Prestige Consumer Healthcare were worth $70,420,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in PBH. UMB Bank n.a. lifted its stake in Prestige Consumer Healthcare by 81.8% during the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares in the last quarter. Maseco LLP purchased a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $27,000. Geneos Wealth Management Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 294.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock valued at $48,000 after buying an additional 447 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PBH. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective for the company in a report on Wednesday, September 24th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Jefferies Financial Group decreased their price target on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research note on Monday, October 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.33.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $59.97 on Friday. Prestige Consumer Healthcare Inc. has a 52 week low of $58.50 and a 52 week high of $90.04. The company has a 50-day moving average price of $62.34 and a 200 day moving average price of $72.54. The company has a market cap of $2.88 billion, a P/E ratio of 14.08, a PEG ratio of 1.93 and a beta of 0.41. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $274.11 million during the quarter, compared to analysts’ expectations of $257.14 million. During the same period last year, the firm earned $1.09 EPS. The company’s quarterly revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.